Adaptation of recombinant activated factor VII in the treatment of acquired haemophilia A: Results from a prospective study (ACQUI-7) in France

Adaptation of recombinant activated factor VII in the treatment of acquired haemophilia A: Results from a prospective study (ACQUI-7) in France

Background: The efficacy and safety of recombinant activated factor VII (rFVIIa; NovoSeven®) in patients with acquired haemophilia A (AHA) are established; however, data on daily use in clinical practice for bleeding episodes are limited. The ACQUI-7 study aimed to provide additional data on managin...

Full description

Bibliographic Details
Main Authors: Benoît Guillet, Achille Aouba, Annie Borel-Derlon, Jeanne Yvonne Borg, Jean-François Schved, Hélène Schneid, Hervé Lévesque
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Thrombosis Update
Subjects:
Acquired haemophilia A
Bleeding episode
Bypassing agents
Daily-use rFVIIa
Observational
Prospective
Online Access:http://www.sciencedirect.com/science/article/pii/S2666572720300213

Internet

http://www.sciencedirect.com/science/article/pii/S2666572720300213

Similar Items